头孢他啶-阿维巴坦组合的临床药代动力学与药效学:模型引导的临床开发策略
阿维巴坦为二氮杂双环辛烷类非β-内酰胺β-内酰胺酶抑制剂,与头孢他啶半衰期均约2小时,适合4:1固定剂量组合。群体PK模型纳入体重、疾病状态、种族和肾功能作为协变量,模拟确定给药方案,使头孢他啶MIC≤8/4 mg/L时达到联合靶值概率。III期研究显示2/0.5 g每8小时2小时输注对复杂腹腔感染、复杂尿路感染和医院获得性肺炎疗效非劣于碳青霉烯类。
要点
- 头孢他啶与阿维巴坦半衰期均约2小时,固定剂量组合比例为4:1。
- 两者主要经肾清除,中重度肾功能不全患者需调整剂量。
- 群体PK模型模拟确定给药方案,III期研究验证了剂量选择与暴露靶值。
核心结论
- 模型引导的策略成功确定了头孢他啶-阿维巴坦的临床给药方案,并获III期研究验证。
研究设计与样本
- 基于群体PK模型模拟确定给药方案,并以杀灭曲线动力学数学模型验证人体剂量选择。
主要发现
- 头孢他啶和阿维巴坦半衰期均约2小时,适合4:1固定剂量组合。
- 两者主要经肾清除,中重度肾功能不全需调整剂量。
- 群体PK模型纳入体重、疾病状态、种族和肾功能(肌酐清除率)作为清除率和分布容积的协变量。
- 给药方案使头孢他啶MIC≤8/4 mg/L时达到联合靶值概率,靶值为50% fT>MIC和50% fT>CT(CT=1 mg/L)。
- III期研究显示2/0.5 g每8小时2小时输注对复杂腹腔感染、复杂尿路感染和医院获得性肺炎非劣于碳青霉烯类。
关键数值与推荐
- 头孢他啶/阿维巴坦固定剂量组合比例为4:1。
- 肾功能正常患者临床给药方案为2/0.5 g每8小时2小时静脉输注,肾功能不全需调整剂量。
- 目标药效学指数为50% fT>MIC(头孢他啶)和50% fT>CT(阿维巴坦CT=1 mg/L)。
- 头孢他啶对肠杆菌科和铜绿假单胞菌的折点为8 mg/L,联合阿维巴坦固定4 mg/L时MIC≤8/4 mg/L。
临床怎么用
- 肾功能正常患者使用2/0.5 g每8小时2小时静脉输注,中重度肾功能不全需调整剂量。
- 治疗目标为覆盖头孢他啶MIC≤8/4 mg/L的肠杆菌科和铜绿假单胞菌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Avibactam is a non-β-lactam, β-lactamase inhibitor of the diazabicyclooctane class that covalently acylates its β-lactamase targets, encompassing extended spectrum of activities that cover serine β-lactamases but not metallo-β-lactamases. Ceftazidime and avibactam have complementary pharmacokinetic (PK) profiles. Both drugs have a half-life of approximately 2 h, making them suitable to be combined in a fixed-dose combination ratio of 4:1 (ceftazidime:avibactam). Renal clearance is the primary elimination pathway of both ceftazidime and avibactam, and dose adjustment is required in patients with moderate and severe renal impairment. Population PK models of ceftazidime and avibactam were developed separately and incorporated body weight, disease state, ethnicity, and renal function (creatinine clearance) as covariates of clearance and volume of distribution. The clinical dosing regimen of ceftazidime/avibactam combination was determined from population PK model simulations in the patient population for dosing regimens that can achieve sufficient joint probability of target attainment for ceftazidime minimum inhibitory concentration (MIC) of 8 mg/L at a fixed 4 mg/L avibactam concentration (MIC ≤ 8/4 mg/L); 8 mg/L is the breakpoint of ceftazidime in Enterobacteriaceae and Pseudomonas aeruginosa for the target pharmacodynamic indices of ceftazidime and avibactam of 50% time at which the free ceftazidime concentration is above the MIC (fT > MIC) and 50% time at which the free avibactam is above a threshold concentration of 1 mg/L (fT > CT). Whereas the static index approach does not take into account the changing potency of ceftazidime in the presence of changing avibactam concentration, a mathematical model based on kill-curve kinetics was utilized to validate the dose selection in humans. The clinical dosing regimen of 2/0.5 g ceftazidime/avibactam administered every 8 h as a 2-h intravenous infusion in patients with normal renal function, with dose adjustment in renal impairment, demonstrated statistical non-inferiority to carbapenem in phase III studies on the treatment of complicated intra-abdominal infection, complicated urinary tract infection, and nosocomial pneumonia, including ceftazidime non-susceptible Gram-negative pathogens. The success of the phase III studies validated the dose selection and exposure target that were associated with efficacy based on a model-informed approach.
引用
- Sy SKB, Zhuang L, Sy S, et al. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development. Clin Pharmacokinet. 2019. PMID: 30097887. doi:10.1007/s40262-018-0705-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。